Abstract library

12 results for "Lo Russo".
#286 Aberrant Expression of FSH Receptor in Pancreatic Neuroendocrine Tumors
Introduction: FSH receptor (FSHR) expression is restricted to gonads. FSHR plays an important role in regulation of ovarian angiogenesis. Recently, FHSR expression has been shown in blood vessels of various tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Fausto Bogazzi
Authors: Russo D, Locci M T, Raggi F, Chifenti B, ...
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#733 Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#1080 Evaluation of the Combination Oxaliplatin and 5-Fluorouracil or Gemcitabine in Patients with Metastatic Lung Carcinoid Tumors
Introduction: -
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: MD, PhD Thomas Walter
Keywords: gemox, folfox, lung, carcinoid
#1082 Characterization and Prognosis of Patients with Metastatic Lung Carcinoid Tumors
Introduction: Data on metastatic lung carcinoid tumors are limited.
Conference: 12th Annual ENETS Conference (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD, PhD Thomas Walter
#1550 Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD, PhD Manuela Albertelli
Keywords: VHL therapy
#1567 Pancreatic Neuroendocrine Tumors: Experience from a Single Institute
Introduction: A dedicated multidisciplinary team is necessary in the management of pancreatic neuroendocrine tumor (pNET).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Andrea Caff
Authors: Caff A, Cordio S, Pellegriti G, Russo M, ...
Keywords: pancreatic, Ki-67
#1725 Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial
Introduction: Anti proliferative effect of LAN ATG 120 mg has been investigated in 204 GI-NET pts in Clarinet study with a 53% reduction in risk of death/progression vs placebo. An increasing number of trials have associated MET with better outcome in cancer pts due to a reduction of insulin/IGF1 levels and modulation of AMPK and TSC1-2/mTOR. The retrospective PRIME-net study conducted on 445 Italian pts, suggest that addition of MET to everolimus and/or SSA provides clinical benefit in diabetic pancreatic NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Sara Pusceddu
Authors: Prinzi N, Femia D, Concas L, Lo Russo G, ...
Keywords: lanreotide, metformin
#1726 A Long-Term Complete Response (CR) of Avelumab in Patient (pt) with Advanced Merkel Cell Carcinoma (MCC)
Introduction: MCC is a rare and aggressive cutaneous neuroendocrine cancer linked to exposure to the Merkel Polyomavirus (MCPyV). Cisplatin and VP16 chemo may be an effective treatment for metastatic MCC, but responses are often transient. The blockade of programmed death 1 (PD-1) immune inhibitory pathway by avelumab, an anti-PD-L1 checkpoint inhibitor, is being investigated in solid neoplasms. This strategy can also be of interest in MCC because these tumors often express PD-L1
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Sara Pusceddu
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.